Benign Prostatic Hyperplasia Therapeutics Market Size, Status, Applications, Technological Improvements and Forecast 2018-2025
A recent report by KD market insights titled as "Benign Prostatic Hyperplasia Therapeutics Market Size, Trends &
Opportunity Outlook – Forecast to 2025" provides the key
trends, opportunities and challenges market will face in the forecasted period
of 6 years i.e. 2016-2025. The study also provides the Benign Prostatic Hyperplasia Therapeutics Market. competitors share
and region wise analysis around the globe.
The prostate is a
walnut-sized gland that surrounds the urethra in the male reproductive system.
The main function of this gland is to secrete a fluid, which mixes with the
fluids from other glands and sperm cells from the testicles to generate semen.
Benign prostatic hyperplasia (BPH) is a non-malignant increase in the size of
the prostate gland. This increase blocks the urine flow from the bladder, which
results in increased urination frequency at night, urinary hesitancy, and
urinary retention. BPH significantly influences the patients quality of life,
owing to symptoms, such as urine leakage and nocturia. If untreated for a long
duration, it results in more serious health issues, such as bladder damage,
bladder stones, kidney damage, and urinary tract infections (UTIs).
The global benign
prostatic hyperplasia therapeutics market was valued at $10,688.72
million in 2017, and is projected to reach $20,096.68 million by 2025 at
a CAGR of 8.1% from 2018 to 2025. This market is majorly
driven by an increase in the male geriatric population because the disease
generally occurs in men of age 60 and above. The other factors boosting the
market growth include growth in awareness related to urological disorders and
prostate cancer and rise in the number of global benign prostatic hyperplasia
patients. However, preferences for minimally-invasive surgeries namely,
laparoscopic prostatectomy, transurethral needle ablation (TUNA), and
transurethral microwave thermotherapy (TUMT), hinder the growth of the global
BPH therapeutics market. Furthermore, presence of a plethora of products in the
pipeline and high market potential in untapped emerging economies are
anticipated to serve as attractive opportunities during the forecast period.
The global benign
prostatic hyperplasia therapeutics market is segmented into therapeutic
class, therapy, and region. On the basis of therapeutic class, the market is
categorized into alpha blocker, 5-alpha reductase inhibitor,
phosphodiesterase-5 inhibitor, and others. As per therapy, the market is
bifurcated into mono drug therapy and combination drug therapy. Region-wise, it
is analyzed across North America, Europe, Asia-Pacific, and Latin America
Middle East and Africa (LAMEA).
KEY BENEFITS
- The study provides an
in-depth analysis of the global benign prostatic hyperplasia therapeutics
market with current trends and future estimations from 2017 to 2025 to
elucidate the imminent investment pockets.
- A comprehensive analysis of factors that drive and restrict the market growth is provided.
- Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on global and regional scales are provided.
- The profiles of key players and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
- A comprehensive analysis of factors that drive and restrict the market growth is provided.
- Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on global and regional scales are provided.
- The profiles of key players and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
Key market segments
By Therapeutic Class
- Alpha blocker
- 5-Alpha reductase inhibitor
- Phosphodiesterase-5 inhibitor
- Others
- 5-Alpha reductase inhibitor
- Phosphodiesterase-5 inhibitor
- Others
By Therapy
- Mono drug therapy
- Combination drug therapy
- Combination drug therapy
By Region
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS
PROFILED IN THE REPORT
- Abbott Laboratories
- Allergan plc
- Astellas Pharma, Inc.
- Boehringer Ingelheim Pharma GmbH & Co. KG
- Eli Lilly and Company
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Pfizer, Inc.
- Sanofi
- Teva Pharmaceutical Industries Limited
- Allergan plc
- Astellas Pharma, Inc.
- Boehringer Ingelheim Pharma GmbH & Co. KG
- Eli Lilly and Company
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Pfizer, Inc.
- Sanofi
- Teva Pharmaceutical Industries Limited
Get Complete Research Report
with TOC @: https://www.kdmarketinsights.com/product/benign-prostatic-hyperplasia-therapeutics-market-amr
Table Of Content:
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for
stakeholders
1.3. Key market segments
1.3.1. List of key players
profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and
models
CHAPTER 2: EXECUTIVE
SUMMARY
2.1. Key findings of the
study
2.2. CXO perspective
CHAPTER 3: MARKET
OVERVIEW
3.1. Market definition and
scope
3.2. Key findings
3.2.1. Top investment
pockets
3.3. Top player
positioning, 2017
3.4. Porters Five Forces
analysis
3.4.1. Bargaining power of
buyers
3.4.2. Bargaining power of
suppliers
3.4.3. Threat of
substitution
3.4.4. Threat of new
entrant
3.4.5. Competitive rivalry
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in in
geriatric population
3.5.1.2. Rise in
prevalence of benign prostatic hyperplasia
3.5.1.3. Growth in the
awareness related to urological disorders and prostate cancer
3.5.2. Restraints
3.5.2.1. High preferences
for minimally invasive surgical therapies
3.5.3. Opportunities
3.5.3.1. Large number of
products in pipeline
3.5.3.2. Opportunities in
emerging economies
3.5.4. Impact analyses
3.6. Clinical trials
CHAPTER 4: BENIGN
PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS
4.1. Overview
4.1.1. Market size and
forecast
4.2. Alpha Blockers
4.2.1. Key market trends,
growth factors and opportunities
4.2.2. Market size and
forecast, by region
4.2.3. Market analysis, by
country
4.3. 5-Alpha Reductase
Inhibitors
4.3.1. Key market trends,
growth factors and opportunities
4.3.2. Market size and
forecast, by region
4.3.3. Market analysis, by
country
4.4. Phosphodiesterase 5
Inhibitor
4.4.1. Key market trends,
growth factors and opportunities
4.4.2. Market size and
forecast, by region
4.4.3. Market analysis, by
country
4.5. Others
4.5.1. Key market trends,
growth factors and opportunities
4.5.2. Market size and
forecast, by region
4.5.3. Market analysis, by
country
CHAPTER 5: BENIGN
PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY
5.1. Overview
5.1.1. Market size and
forecast
5.2. Mono Drug Therapy
5.2.1. Market size and
forecast, by region
5.2.2. Market analysis, by
country
5.3. Combination Drug
Therapy
5.3.1. Market size and
forecast, by region
5.3.2. Market analysis, by
country
CHAPTER 6: BENIGN
PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and
forecast
6.2. North America
6.2.1. Key market trends,
growth factors and opportunities
6.2.2. North America
benign prostatic hyperplasia therapeutics market, by country
6.2.2.1. U.S.
6.2.2.1.1. Market size and
forecast, by therapeutic class
6.2.2.1.2. Market size and
forecast, by therapy
6.2.2.2. Canada
6.2.2.2.1. Market size and
forecast, by therapeutic class
6.2.2.2.2. Market size and
forecast, by therapy
6.2.2.3. Mexico
6.2.2.3.1. Market size and
forecast, by therapeutic class
6.2.2.3.2. Market size and
forecast, by therapy
6.2.3. North America
market size and forecast, by therapeutic class
6.2.4. North America
market size and forecast, by therapy
6.3. Europe
6.3.1. Key market trends,
growth factors and opportunities
6.3.2. Europe market size
and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Market size and
forecast, by therapeutic class
6.3.2.1.2. Market size and
forecast, by therapy
6.3.2.2. France
6.3.2.2.1. Market size and
forecast, by therapeutic class
6.3.2.2.2. Market size and
forecast, by therapy
6.3.2.3. UK
6.3.2.3.1. Market size and
forecast, by therapeutic class
6.3.2.3.2. Market size and
forecast, by therapy
6.3.2.4. Italy
6.3.2.4.1. Market size and
forecast, by therapeutic class
6.3.2.4.2. Market size and
forecast, by therapy
6.3.2.5. Spain
6.3.2.5.1. Market size and
forecast, by therapeutic class
6.3.2.5.2. Market size and
forecast, by therapy
6.3.3. Rest of Europe
6.3.3.1.1. Market size and
forecast, by therapeutic class
6.3.3.1.2. Market size and
forecast, by therapy
6.3.4. Europe market size
and forecast, by therapeutic class
6.3.5. Europe market size
and forecast, by therapy
6.4. Asia-Pacific
6.4.1. Key market trends,
growth factors and opportunities
6.4.2. Asia-Pacific market
size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Market size and
forecast, by therapeutic class
6.4.2.1.2. Market size and
forecast, by therapy
6.4.2.2. China
6.4.2.2.1. Market size and
forecast, by therapeutic class
6.4.2.2.2. Market size and
forecast, by therapy
6.4.2.3. India
6.4.2.3.1. Market size and
forecast, by therapeutic class
6.4.2.3.2. Market size and
forecast, by therapy
6.4.2.4. Australia
6.4.2.4.1. Market size and
forecast, by therapeutic class
6.4.2.4.2. Market size and
forecast, by therapy
6.4.2.5. South Korea
6.4.2.5.1. Market size and
forecast, by therapeutic class
6.4.2.5.2. Market size and
forecast, by therapy
6.4.2.6. Rest of
Asia-Pacific
6.4.2.6.1. Market size and
forecast, by therapeutic class
6.4.2.6.2. Market size and
forecast, by therapy
6.4.3. Asia-Pacific market
size and forecast, by therapeutic class
6.4.4. Asia-Pacific market
size and forecast, by therapy
6.5. LAMEA
6.5.1. Key market trends,
growth factors and opportunities
6.5.2. LAMEA market size
and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Market size and
forecast, by therapeutic class
6.5.2.1.2. Market size and
forecast, by therapy
6.5.2.2. Saudi Arabia
6.5.2.2.1. Market size and
forecast, by therapeutic class
6.5.2.2.2. Market size and
forecast, by therapy
6.5.2.3. South Africa
6.5.2.3.1. Market size and
forecast, by therapeutic class
6.5.2.3.2. Market size and
forecast, by therapy
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Market size and
forecast, by therapeutic class
6.5.2.4.2. Market size and
forecast, by therapy
6.5.3. LAMEA market size
and forecast, by therapeutic class
6.5.4. LAMEA market size
and forecast, by therapy
Continue:
About Us:
KD Market Insights offers a comprehensive database of syndicated
research studies, customized reports, and consulting services. These reports
are created to help in making smart, instant and crucial decisions based on
extensive and in-depth quantitative information, supported by extensive
analysis and industry insights.
Our dedicated in-house team ensures the reports satisfy the requirement
of the client. We aim at providing value service to our clients. Our reports
are backed by extensive industry coverage and is made sure to give importance
to the specific needs of our clients. The main idea is to enable our clients to
make an informed decision, by keeping them and ourselves up to date with the
latest trends in the market.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
Telephone: +1 (516) 300-1215
Comments
Post a Comment